Excretion of wild-type and vaccine-derived poliovirus in the feces of poliovirus receptor-transgenic mice

Journal of Virology

Volumn 77, Issue 11, 2003, Pages 6541-6545

  Boot, Hein J ^a   Kasteel, Daniella T J ^a,b   Buisman, Anne Marie ^a   Kimman, Tjeerd G ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE TRANSMISSION; FECES ANALYSIS; INFECTION CONTROL; INFECTION RISK; MOUSE; NONHUMAN; PHENOTYPE; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RECEPTOR GENE; STRAIN DIFFERENCE; VACCINATION; VACCINE DERIVED POLIOVIRUS; VIRUS TRANSMISSION;

ANIMALS; FECES; HUMANS; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RECEPTORS, VIRUS; SEROTYPING; VACCINATION; VACCINES, INACTIVATED; VIRUS SHEDDING;

EID: 0038702523     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.11.6541-6545.2003     Document Type: Article

References (20)

1. Buisman, A. M., J. A. Sonsma, T. G. Kimman, and M. P. Koopmans. 2000. Mucosal and systemic immunity against poliovirus in mice transgenic for the poliovirus receptor: the poliovirus receptor is necessary for a virus-specific mucosal IgA response. J. Infect. Dis. 181:815-823.
2. Centers for Disease Control and Prevention. 2000. Outbreak of poliomyelitis-Dominican Republic and Haiti, 2000. Morb. Mortal. Wkly. Rep. 49:1094-1103.
3. Centers for Disease Control and Prevention. 2001. Acute flaccid paralysis associated with circulating vaccine-derived poliovirus-Philippines, 2001. Morb. Mortal. Wkly. Rep. 50:874-875.
4. Centers for Disease Control and Prevention. 2001. Circulation of a type 2 vaccine-derived poliovirus-Egypt, 1982-1993. Morb. Mortal. Wkly. Rep. 50:41-42.
5. Centers for Disease Control and Prevention. 2002. Poliomyelitis-Madagascar, 2002. Morb. Mortal. Wkly. Rep. 51:662.
6. Centers for Disease Control and Prevention. 2002. Progress toward global eradication of poliomyelitis, 2001. Morb. Mortal. Wkly. Rep. 51:253-256.
7. Cherkasova, E. A., E. A. Korotkova, M. L. Yakovenko, O. E. Ivanova, T. P. Eremeeva, K. M. Chumakov, and V. I. Agol. 2002. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J. Virol. 76:6791-6799.
8. Crotty, S., L. Hix, L. J. Sigal, and R. Andino. 2002. Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J. Gen. Virol. 83:1707-1720.
9. Cuervo, N. S., S. Guillot, N. Romanenkova, M. Combiescu, A. Aubert-Combiescu, M. Seghier, V. Caro, R. Crainic, and F. Delpeyroux. 2001. Genomic features of intertypic recombinant Sabin poliovirus strains excreted by primary vaccinees. J. Virol. 75:5740-5751.
10. Dowdle, W. R. 2001. Polio eradication: turning the dream into reality. ASM News 67:397-402.
11. Fine, P. E., and I. A. Carneiro. 1999. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am. J. Epidemiol. 150:1001-1021.
12. Furione, M., S. Guillot, D. Otelea, J. Balanant, A. Candrea, and R. Crainic. 1993. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196:199-208.
13. Guillot, S., V. Caro, N. Cuervo, E. Korotkova, M. Combiescu, A. Persu, A. Aubert-Combiescu, F. Delpeyroux, and R. Crainic. 2000. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J. Virol. 74:8434-8443.
14. Kew, O., V. Morris-Glasgow, M. Landaverde, C. Burns, J. Shaw, Z. Garib, J. Andre, E. Blackman, C. J. Freeman, J. Jorba, R. Sutter, G. Tambini, L. Venczel, C. Pedreira, F. Laender, H. Shimizu, T. Yoneyama, T. Miyamura, H. van Der Avoort, M. S. Oberste, D. Kilpatrick, S. Cochi, M. Pallansch, and C. de Quadros. 2002. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296:356-359.
15. Minor, P. D. 1993. Attenuation and reversion of the Sabin vaccine strains of poliovirus. Dev. Biol. Stand. 78:17-26.
16. Nkowane, B. M., S. G. Wassilak, W. A. Orenstein, K. J. Bart, L. B. Schonberger, A. R. Hinman, and O. M. Kew. 1987. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 257:1335-1340.
17. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent end points. Am. J. Hygiene 27:493-497.
18. Ren, R. B., F. Costantini, E. J. Gorgacz, J. J. Lee, and V. R. Racaniello. 1990. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63:353-362.
19. Shulman, L. M., Y. Manor, R. Handsher, F. Delpeyroux, M. J. McDonough, T. Halmut, I. Silberstein, J. Alfandari, J. Quay, T. Fisher, J. Robinov, O. M. Kew, R. Crainic, and E. Mendelson. 2000. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 38:3729-3734.
20. Zhang, S., and V. R. Racaniello. 1997. Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. J. Virol. 71:4915-4920.